title: Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology.
abstract: Human papillomavirus type 16 (HPV16) may infect the cervical epithelium without producing pathological changes for a long time. To investigate if mucosal antibodies are induced in HPV16-infected women without visible pathology, cervical mucus from HPV16-infected patients with and without evident pathology, along with mucus from uninfected women were analyzed for the presence of mucosal IgG and secretory IgA (sIgA) antibodies to HPV16 capsid proteins by ELISA. sIgA and IgG antibodies were found in a significantly higher proportion of infected patients compared with uninfected women (p < 0.0001). sIgA antibodies were present in 13.1% of infected patients without visible pathology, the proportion of positivity increased to 27.0% in patients with visible pathology (p = 0.001). Mucosal IgG response was observed in 6.5% of patients without and 27.5% of patients with visible pathology (p = 0.00005). The antibody mean signal strength was significantly higher in patients with than in patients without pathological evidence (p < 0.005). In conclusion, both sIgA and IgG are found in patients without pathological signs of infection, however, the response increases significantly in patients with pathological evidence, suggesting that the appearance of these changes might be associated with a more vigorous antibody-mediated mucosal reaction.
authors.affiliation: Department of Molecular Biology and Biotechnology, General Hospital of Mexico, Mexico City, Mexico.
authors.forename: L
authors.initials: L
authors.lastname: Rocha-Zavaleta
authors.forename: A L
authors.initials: AL
authors.lastname: Pereira-Suarez
authors.forename: G
authors.initials: G
authors.lastname: Yescas
authors.forename: R M
authors.initials: RM
authors.lastname: Cruz-Mimiaga
authors.forename: A
authors.initials: A
authors.lastname: Garcia-Carranca
authors.forename: F
authors.initials: F
authors.lastname: Cruz-Talonia
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology*; D002584:Cervix Uteri / Q000276:immunology*; D005260:Female; D006801:Humans; D018928:Immunity, Mucosal; D007071:Immunoglobulin A, Secretory / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology*; D008875:Middle Aged; D009092:Mucous Membrane / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D015995:Prevalence; D002577:Uterine Cervical Diseases / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000276:immunology / Q000821:virology
chemical_list: D000914:Antibodies, Viral; D036022:Capsid Proteins; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G